- Mar 11, 2026 Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
- Feb 24, 2026 Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
- Feb 23, 2026 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
- Feb 03, 2026 Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
- Jan 13, 2026 Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
- Jan 09, 2026 Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
- Nov 25, 2025 Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
- Nov 05, 2025 Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
- Nov 03, 2025 Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
- Oct 30, 2025 Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Displaying 1 - 10 of 115